In Brief: Interpore
This article was originally published in The Gray Sheet
Executive Summary
Interpore: Receives FDA go-ahead to commence a 20-patient pilot study of its Pro Osteon Implant 500 "as an autograft donor site backfill material." Slated to begin in the third quarter, the trial will evaluate the product's "impact on reducing pain and healing time" in lumbar spine fusion procedures, "where bone material harvested from the patient's iliac crest is used at the spinal fusion site." Ten patients in the study will receive Pro Osteon; 10 patients will receive autograft treatment without Pro Osteon...
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.